Donepezil Hydrochloride Tablets, 23 mg
Dr. Reddy’s Laboratories
ARICEPT (Eisai, Inc, and Pfizer, Inc)
Dr. Reddy’s Laboratories has launched donepezil hydrochloride, 23 mg, a therapeutic generic equivalent of Eisai, Inc’s, and Pfizer, Inc’s, ARICEPT, 23 mg, following FDA approval of its abbreviated new drug application. The drug is indicated for the treatment of dementia associated with moderate to severe Alzheimer’s disease. Donepezil hydrochloride tablets, 23 mg, can be administered once daily after patients have been on a 10-mg dose for at least 3 months. Donepezil hydrochloride tablets, 23 mg, is available in bottle counts of 30 and 90.
Tablets: 23 mg
For More Information: www.drreddys.com
Bromfed DM (Wockhardt)
Bromfed DM offers physician-directed prescription therapy for cough and nasal congestion associated with allergies and the common cold for children as young as 2 years of age. It is non-narcotic. The recommended dose is 2 teaspoonfuls every 4 hours for adults and children 12 years and older, 1 teaspoonful every 4 hours for children 6 to 11 years, and half a teaspoonful every 4 hours for children 2 to 5 years.
Syrup, oral, 1 teaspoonful (5 mL): 2 mg brompheniramine maleate, 10 mg dextromethorphan hydrobromide, and 30 mg pseudoephedrine hydrochloride
For More Information: www.wockhardtusa.com
Fenofibric Acid EQ Delayed-Release Capsules
Par Pharmaceutical Companies, Inc, has received FDA approval for its abbreviated new drug application for fenofibric acid EQ delayed-release capsules. It is the generic version of AbbVie’s Trilipix and is indicated to reduce triglycerides and increase high-density lipoprotein cholesterol in patients with mixed dyslipidemia and coronary heart disease in combination with a statin, or to help patients at risk of coronary heart disease who are on optimal statin therapy achieve their low-density lipoprotein cholesterol goal. It is also indicated as monotherapy; see the prescribing information for details.
Capsules: 45 and 135 mg
For More Information: www.parpharm.com
Acitretin Capsules, USP
Soriatane Capsules (Stiefel Labs)
Teva introduces acitretin capsules, USP, a generic version of Stiefel Labs’ Soriatane. It is indicated for the treatment of severe psoriasis in adults. Therapy should be given as a single dose with a main meal, and patients should be aware that a number of more common side effects are dose related. Due to the risk of birth defects, women who are or intend to become pregnant within 3 years of discontinuing therapy should not use acitretin capsules.
Capsules: 10, 17.5, and 25 mg
For More Information: www.tevagenerics.com